Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BeiGene Ltd ( (HK:6160) ) just unveiled an announcement.
BeiGene, Ltd. has announced that it will release its fourth quarter and full year 2024 financial results on February 27, 2025. The announcement will be followed by an audit committee meeting to approve the audited financial results, which will be prepared in accordance with U.S. GAAP and SEC rules. A conference call with BeiGene management will be held on the same day, and the results will also be published on the company’s website. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and adherence to international financial reporting standards.
More about BeiGene Ltd
BeiGene, Ltd. operates in the biotechnology industry, focusing on discovering, developing, and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
YTD Price Performance: 23.53%
Average Trading Volume: 1,903,284
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$195.1B
For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.
